PVR and leukemia: Stimulation of DNAM-1 by its ligands CD155 (poliovirus receptor) and CD112 (nectin-2) expressed on different types of tumors including melanoma, leukemia, and ovarian carcinoma leads to NK cell activation and target cell lysis.